VivoSeq
Cardiovascular

Aortic Aneurysm

11

Pipeline Programs↗

7

Active Trials↗

6

Companies Involved↗

Aortic Aneurysm is an emerging landscape with 11 programs across 6 companies. The most active players are Neurim Pharmaceuticals Ltd., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Teva. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

22/100

Mech. Concentration

20/100

Completion Rate

88/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedTeva logo

Teva

1 program

ApprovedChiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

1 program

PreclinicalM

Microvascular Therapeutics, LLC

1 program

PreclinicalV

Vascutek Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed7 · 41%
Recruiting5 · 29%
Unknown status2 · 12%
Withdrawn1 · 6%
Active, not recruiting1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

A Prospective, Single-center, Open-label Study of Lipid Metabolism and Mitochondrial Function in Myeloid Cells and Total Aortic Tissue in Patients With Ascending Thoracic Aortic Aneurysm (ATA) and Bicuspid (BA) or Tricuspid (TA) Aortic Valves.
Recruiting·CCentre Hospitalier Universitaire Dijon·N/A·NCT07695545·50 enrolled
Prospective Evaluation of Physician Modified Endografts for Aortic Disease
Recruiting·MMayo Clinic·Preclinical·NCT07611968·20 enrolled
Evaluation of the Rapidlink Device for Use in the Repair or Replacement of the Supra-Aortic Vessels During an Open Surgical Procedure of the Thoracic Aorta
Recruiting·VVascutek Ltd.·Preclinical·NCT07078383·150 enrolled
Comparison of Femorofemoral Bypass and Left-Heart Bypass Techniques in Open Thoracoabdominal Aortic Aneurysm Repair: A Study Protocol for Multicenter, Two-Arm, Open-Label, Randomized, ParalleI-Controlled Non-Inferiority Trial
Recruiting·BBeijing Anzhen Hospital·Preclinical·NCT07518251·236 enrolled
Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms
Recruiting·TThe Cleveland Clinic·Preclinical·NCT06657794·15 enrolled
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)
Active, not recruiting·FFrench Cardiology Society·N/A·NCT05146375·17 enrolled
Outcomes of Left Subclavian Artery Revascularization Strategies During Zone 2 Thoracic Endovascular Aortic Repair
Not yet recruiting·AAssiut University·Preclinical·NCT07697820·50 enrolled
Magnetic Resonance Imaging of Aortic Aneurysm Instability
Completed·UUniversity of Edinburgh·Phase 2/3·NCT00794092·29 enrolled
Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair
Completed·—·N/A·NCT00126204·75 enrolled
Evaluation of Predictors of Aortic Aneurysm Growth and Rupture
Completed·—·Phase 2·NCT02022436·66 enrolled
Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair
Completed·—·N/A·NCT01005212·20 enrolled
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Completed·IImperial College London·Phase 2·NCT01118520·224 enrolled
The Gender Specific Effect on the Results of Ascending Aortic Replacement in Small Ascending Aortic Aneurysm
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·N/A·NCT04905225·200 enrolled
Biomechanical and Elastic Properties of the Ascending Wall of the Human Aorta in Aneurysm
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·Preclinical·NCT05839990·50 enrolled
Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection
Withdrawn·—·N/A·NCT01480531
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)